Vol. 5 No. 3 (2025)
Reimbursement Reviews

Ciltacabtagene Autoleucel (Carvykti)

decorative image of the issue cover

Published March 31, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ciltacabtagene autoleucel (Carvykti), cell suspension in infusion bag, 0.5 × 106 to 1.0 × 106 CAR-positive viable T cells per kilogram of body weight, with a maximum of 1 × 108 CAR-positive viable T cells, for IV infusion.
  • Indication: For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.